Trial Profile
An International, Multicenter, Randomized, Placebo-controlled, Parallel-group, 1 Year Treatment, Integrated Biomarkers and Imaging Study in Subjects With Angiographically Documented Coronary Heart Disease (CHD) to Examine the Effects of the Novel Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor SB-480848 on Intermediate Cardiovascular Endpoints, Patient Safety and Tolerability
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Darapladib (Primary)
- Indications Atherosclerosis; Coronary artery disease
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic
- Acronyms IBIS-2
- Sponsors GlaxoSmithKline; GSK
- 20 May 2009 Trial phase changed from II/III to II as reported by ClinicalTrials.gov record.
- 12 May 2009 Additional location Spain identified as reported by ClinicalTrials.gov.
- 03 Sep 2008 Results have been presented in a Hotline session at ESC Congress 2008: Annual Congress of the European Society of Cardiology.